Derleme
BibTex RIS Kaynak Göster

Tümör Lizis Sendromunda Hemşirelik Yaklaşımı

Yıl 2021, Cilt: 4 Sayı: 1, 113 - 122, 18.04.2021
https://doi.org/10.38108/ouhcd.782461

Öz

Tümör lizis sendromu, hızlı hücre ölümünden kaynaklanan onkometabolik acil bir durumdur. Tümör lizis sendromu, tümör hedefli tedavinin bir sonucu olarak veya kendiliğinden ortaya çıkabilmektedir. Bu çalışmanın amacı tümör lizis sendromu ve hemşirelik bakımı ile ilgili literatür bilgisinin derlenmesidir. Tümör lizis sendromunun laboratuvar ve klinik belirti bulguları ile ilgili olarak kanser hastası yakından izlenmeli, yüksek risk grubundaki hastalara yeterli hidrasyon, fosfat bağlayıcıların kullanımı, ürik asit düşürücü tedavi ve hastanın potasyum alımının azaltılması gibi önleyici girişimlerin uygulanması önemlidir. Sağlık profesyoneli olan onkoloji ve yoğun bakım hemşireleri, hastanede yatan her kanser hastasını ve özellikle kemoterapi görenleri tümör lizis sendromu riski açısından sınıflandırarak kanser hastasına destekleyici bakım vermelidir.

Destekleyen Kurum

Bulunmamaktadır

Kaynakça

  • Kaynaklar Adeyinka A, Bashir K. (2019). Tumor lysis syndrome. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK518985/. Erişim tarihi: 12.07.2020.
  • Alakel N, Middeke JM, Schetelig J, Bornhäuser M. (2017). Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. OncoTargets and Therapy, 10, 597-605.
  • Belay Y, Yirdaw K, Enawgaw B. (2017). Tumor lysis syndrome in patients with hematological malignancies. Journal of Oncology, 17; 9684909.
  • Beth McGraw RN. (2008). At an increased risk: tumor lysis syndrome. Clinical Journal of Oncology Nursing, 12(4), 563-565.
  • British Thoracic Society Nebulizer Project Group (1997). Current best practice for nebuliser treatment. Thorax, 52(2), 1-3.
  • Pace A.F., (2015). Electrolyte ımbalances, syndrome of ınappropriate antidıuretic hormone, and tumor lysis synedrome. Brown CG. (Ed). A Guide to Oncology Symptom Management. Pittsburg: ONS, p. 319-68.
  • Cairo MS, Bishop M. (2004). Tumour lysis syndrome: new therapeutic strategies and classification. British Journal of Hematology, 127(1), 3-11.
  • Criscuolo M, Fianchi L, Dragonetti G, Pagano L. (2016). Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. Expert Review of Hematology, 9(2), 197-208.
  • Coiffier B, Riouffol C. (2007). Management of tumor lysis syndrome in adults. Expert Review of Anticancer Therapy, 7(2), 233-239.
  • Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay É. (2010). Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leukemia & Lymphoma, 51(2), 221-227.
  • Edeani A, Shirali A. (2017). Chapter 4: Tumor lysis syndrome. Onco-Nephrology Curriculum, Mark A. Perazella editor. Washington, DC: American Society of Nephrology, p.1-8.
  • Held-Warmkessel J. (2010). How to prevent and manage tumor lysis syndrome. Nursing 2019, 40(2), 26-31.
  • Hüzmeli, C. (2019). Assessment of tumor lysis syndrome cases. Cumhuriyet Tıp Dergisi, 41(1), 28-33.
  • Hochberg J, Cairo MS. (2008). Rasburicase: future directions in tumor lysis management. Expert Opinion on Biological Therapy, 8(10), 1595-1604.
  • Garimella PS, Balakrishnan P, Ammakkanavar NR, Patel S, Patel A, Konstantinidis I, Nadkarni, GN. (2017). Impact of dialysis requirement on outcomes in tumor lysis syndrome. Nephrology, 22(1), 85-88.
  • Gönderen Çakmak H.S. (2020). Tümör lizis sendromu. Kapucu S., Kutlutürkan S. (Editörler). Hemşirelik Öğrencilerine Yönelik Onkoloji Hemşireliği. Ankara: Hipokrat yayıncılık, s.447-453.
  • Kaplow R, Iyere K. (2016). Recognizing and preventing tumor lysis syndrome. Nursing 2019, 46(11), 26-32.
  • Jones GL, Will A, Jackson GH, Webb NJ, Rule S, British Committee for Standards in Haematology. (2015). Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. British Journal of Haematology, 169(5), 661-671.
  • Mackiewicz T. (2012). Prevention of tumor lysis syndrome in an outpatient setting. Clinical Journal of Oncology Nursing, 16(2),189-193.
  • Mirrakhimov AE, Voore P, Khan M, Ali AM. (2015). Tumor lysis syndrome: a clinical review. World Journal of Critical Care Medicine, 4(2), 130-138.
  • Puri I, Sharma D, Gunturu KS, Ahmed AA. (2020). Diagnosis and management of tumor lysis syndrome. Journal of Community Hospital Internal Medicine Perspectives, 10(3), 269-272.
  • Özen AT, Enç N. (2013). Kritik hastalıklarda sıvı elektrolit dengesi değişikliklerinde hemşirenin rolü. Kardiyovasküler Hemşirelik Dergisi, 4(5), 9-13.
  • Sarno J. (2013). Prevention and management of tumor lysis syndrome in adults with malignancy. Journal of the Advanced Practitioner in Oncology, 4(2), 101-106.
  • Sleutel MR, Brown W, Wells JN. (2016). Preventing Tumor Lysis Syndrome: Two Case Studies of Unexpected Outcomes. Clinical Journal of Oncology Nursing, 20(2), 195-200.
  • Strauss PZ, Hamlin SK, Dang J. (2017). Tumor lysis syndrome: a unique solute disturbance. Nursing Clinics, 52(2), 309-320.
  • Taho-Tammy T, Winokur EJ. (2019). Tumor Lysis Syndrome: A Practical Guide for Nurse Practitioners. The Journal for Nurse Practitioners, 15(9), 636-639.
  • Zafrani L, Canet E, Darmon M. (2019). Understanding tumor lysis syndrome. Intensive Care Medicine, 45(11), 1608-1611.
  • Wilson FP, Berns JS. (2014). Tumor lysis syndrome: new challenges and recent advances. Advances in Chronic Kidney Disease, 21(1), 18-26.
  • Williams SM, Killeen AA. (2019). Tumor lysis syndrome. Archives of Pathology & Laboratory Medicine, 143(3), 386-393.

Nursing Approach in Tumor Lysis Syndrome

Yıl 2021, Cilt: 4 Sayı: 1, 113 - 122, 18.04.2021
https://doi.org/10.38108/ouhcd.782461

Öz

Tumor lysis syndrome is an oncometabolic emergency caused by rapid cell death. Tumor lysis syndrome can occur spontaneously or as a result of tumor-targeted therapy. The aim of this study is to review the literature on Tumor Lysis Syndrome and nursing care.
The cancer patient should be closely monitored regarding the laboratory and clinical symptoms of tumor lysis syndrome, and preventive interventions such as adequate hydration, use of phosphate binders, uric acid-lowering treatment and reduction of the patient's potassium intake are important in high-risk patients. Oncology and intensive care nurses, who are health professionals, should classify each hospitalized cancer patient and especially those receiving chemotherapy in terms of tumor lysis syndrome risk and provide supportive care to the cancer patient.

Kaynakça

  • Kaynaklar Adeyinka A, Bashir K. (2019). Tumor lysis syndrome. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK518985/. Erişim tarihi: 12.07.2020.
  • Alakel N, Middeke JM, Schetelig J, Bornhäuser M. (2017). Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. OncoTargets and Therapy, 10, 597-605.
  • Belay Y, Yirdaw K, Enawgaw B. (2017). Tumor lysis syndrome in patients with hematological malignancies. Journal of Oncology, 17; 9684909.
  • Beth McGraw RN. (2008). At an increased risk: tumor lysis syndrome. Clinical Journal of Oncology Nursing, 12(4), 563-565.
  • British Thoracic Society Nebulizer Project Group (1997). Current best practice for nebuliser treatment. Thorax, 52(2), 1-3.
  • Pace A.F., (2015). Electrolyte ımbalances, syndrome of ınappropriate antidıuretic hormone, and tumor lysis synedrome. Brown CG. (Ed). A Guide to Oncology Symptom Management. Pittsburg: ONS, p. 319-68.
  • Cairo MS, Bishop M. (2004). Tumour lysis syndrome: new therapeutic strategies and classification. British Journal of Hematology, 127(1), 3-11.
  • Criscuolo M, Fianchi L, Dragonetti G, Pagano L. (2016). Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. Expert Review of Hematology, 9(2), 197-208.
  • Coiffier B, Riouffol C. (2007). Management of tumor lysis syndrome in adults. Expert Review of Anticancer Therapy, 7(2), 233-239.
  • Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay É. (2010). Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leukemia & Lymphoma, 51(2), 221-227.
  • Edeani A, Shirali A. (2017). Chapter 4: Tumor lysis syndrome. Onco-Nephrology Curriculum, Mark A. Perazella editor. Washington, DC: American Society of Nephrology, p.1-8.
  • Held-Warmkessel J. (2010). How to prevent and manage tumor lysis syndrome. Nursing 2019, 40(2), 26-31.
  • Hüzmeli, C. (2019). Assessment of tumor lysis syndrome cases. Cumhuriyet Tıp Dergisi, 41(1), 28-33.
  • Hochberg J, Cairo MS. (2008). Rasburicase: future directions in tumor lysis management. Expert Opinion on Biological Therapy, 8(10), 1595-1604.
  • Garimella PS, Balakrishnan P, Ammakkanavar NR, Patel S, Patel A, Konstantinidis I, Nadkarni, GN. (2017). Impact of dialysis requirement on outcomes in tumor lysis syndrome. Nephrology, 22(1), 85-88.
  • Gönderen Çakmak H.S. (2020). Tümör lizis sendromu. Kapucu S., Kutlutürkan S. (Editörler). Hemşirelik Öğrencilerine Yönelik Onkoloji Hemşireliği. Ankara: Hipokrat yayıncılık, s.447-453.
  • Kaplow R, Iyere K. (2016). Recognizing and preventing tumor lysis syndrome. Nursing 2019, 46(11), 26-32.
  • Jones GL, Will A, Jackson GH, Webb NJ, Rule S, British Committee for Standards in Haematology. (2015). Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. British Journal of Haematology, 169(5), 661-671.
  • Mackiewicz T. (2012). Prevention of tumor lysis syndrome in an outpatient setting. Clinical Journal of Oncology Nursing, 16(2),189-193.
  • Mirrakhimov AE, Voore P, Khan M, Ali AM. (2015). Tumor lysis syndrome: a clinical review. World Journal of Critical Care Medicine, 4(2), 130-138.
  • Puri I, Sharma D, Gunturu KS, Ahmed AA. (2020). Diagnosis and management of tumor lysis syndrome. Journal of Community Hospital Internal Medicine Perspectives, 10(3), 269-272.
  • Özen AT, Enç N. (2013). Kritik hastalıklarda sıvı elektrolit dengesi değişikliklerinde hemşirenin rolü. Kardiyovasküler Hemşirelik Dergisi, 4(5), 9-13.
  • Sarno J. (2013). Prevention and management of tumor lysis syndrome in adults with malignancy. Journal of the Advanced Practitioner in Oncology, 4(2), 101-106.
  • Sleutel MR, Brown W, Wells JN. (2016). Preventing Tumor Lysis Syndrome: Two Case Studies of Unexpected Outcomes. Clinical Journal of Oncology Nursing, 20(2), 195-200.
  • Strauss PZ, Hamlin SK, Dang J. (2017). Tumor lysis syndrome: a unique solute disturbance. Nursing Clinics, 52(2), 309-320.
  • Taho-Tammy T, Winokur EJ. (2019). Tumor Lysis Syndrome: A Practical Guide for Nurse Practitioners. The Journal for Nurse Practitioners, 15(9), 636-639.
  • Zafrani L, Canet E, Darmon M. (2019). Understanding tumor lysis syndrome. Intensive Care Medicine, 45(11), 1608-1611.
  • Wilson FP, Berns JS. (2014). Tumor lysis syndrome: new challenges and recent advances. Advances in Chronic Kidney Disease, 21(1), 18-26.
  • Williams SM, Killeen AA. (2019). Tumor lysis syndrome. Archives of Pathology & Laboratory Medicine, 143(3), 386-393.
Toplam 29 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Hemşirelik
Bölüm Derleme
Yazarlar

Nazli Öztürk 0000-0003-2108-0735

Fatma Arıkan 0000-0003-0481-1903

Yayımlanma Tarihi 18 Nisan 2021
Gönderilme Tarihi 19 Ağustos 2020
Yayımlandığı Sayı Yıl 2021 Cilt: 4 Sayı: 1

Kaynak Göster

APA Öztürk, N., & Arıkan, F. (2021). Tümör Lizis Sendromunda Hemşirelik Yaklaşımı. Ordu Üniversitesi Hemşirelik Çalışmaları Dergisi, 4(1), 113-122. https://doi.org/10.38108/ouhcd.782461